RT Journal Article
SR Electronic
T1 Computational Modeling Identifies Embolic Stroke of Undetermined Source Patients with Potential Arrhythmic Substrate
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.03.20184051
DO 10.1101/2020.09.03.20184051
A1 Savannah F. Bifulco
A1 Griffin D. Scott
A1 Sakher Sarairah
A1 Zeinab Birjandian
A1 Caroline H. Roney
A1 Steven A. Niederer
A1 Christian Mahnkopf
A1 Peter Kuhnlein
A1 Marcel Mitlacher
A1 David Tirschwell
A1 W. T. Longstreth, Jr
A1 Nazem Akoum
A1 Patrick M. Boyle
YR 2021
UL http://medrxiv.org/content/early/2021/03/24/2020.09.03.20184051.abstract
AB Cardiac magnetic resonance imaging (MRI) has revealed fibrosis in embolic stroke of undetermined source (ESUS) patients comparable to levels seen in atrial fibrillation (AFib). We used computational modeling to understand the absence of arrhythmia in ESUS despite the presence of putatively pro-arrhythmic fibrosis. MRI-based atrial models were reconstructed for 45 ESUS and 45 AFib patients. The fibrotic substrate’s arrhythmogenic capacity in each patient was assessed computationally. Reentrant drivers were induced in 24/45 (53%) ESUS and 22/45 (49%) AFib models. Inducible models had more fibrosis (16.7±5.45%) than non-inducible models (11.07±3.61%; P<0.0001); however, inducible subsets of ESUS and AFib models had similar fibrosis levels (P=0.90), meaning the intrinsic pro-arrhythmic substrate properties of fibrosis in ESUS and AFib are indistinguishable. This suggests some ESUS patients have latent pre-clinical fibrotic substrate that could be a future source of arrhythmogenicity. Thus, our work prompts the hypothesis that ESUS patients with fibrotic atria are spared from AFib due to an absence of arrhythmia triggers.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialn/a this study is not a clinical trialFunding StatementSFB is supported by a fellowship from the ARCS foundation. CHR is supported by a Medical Research Council Skills Development Fellowship (MR/S015086/1). SAN is supported by NIH R01-HL152256, ERC PREDICT-HF (864055), BHF (RG/20/4/34803), EPSRC (EP/P01268X/1), and the Wellcome Trust (203148/Z/16/Z). DT and WTL are co-PIs for the ARCADIA trial (NIH 5-U01-NS095869), which receives in-kind study drug from the BMS-Pfizer Alliance and ancillary funding from Roche Diagnostics. NA is supported by John Locke Charitable Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients were recruited to undergo cardiac LGE-MRI from the University of Washington (Seattle, WA) and Klinikum Coburg (Coburg, Germany) between July 2016 and June 2019. It was approved by the Institutional Review Board (IRB) of the University of Washington (UW) and the Ethikkommission der Bayerischen Ländesärztekammer München, Bayern, Deutschland; all participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFollowing publication, relevant data will be made available by the authors in response to reasonable requests for non-commercial reuse upon approval from the relevant Independent Ethics Committee(s).